Boehringer Ingelheim has announced the launch of Mirapexin (pramipexole) as a new once-daily prolonged-release tablet for the treatment of Parkinson's disease (PD).
The new treatment is expected to provide a welcome boost for patients who will benefit from the new dosing regimen as they only have to remember to take the medicine once.
The company also believes that most patients on the three-times-a-day formulation should be able to switch to the once daily prolonged release formulation overnight.
This recommendation is based on clinical trials, in which almost 85% of patients successfully switched to the once-daily overnight.
University College London professor Andrew Lees said that learning to accept and live with PD is crucially important to the long-term wellbeing of patients.
"Having different treatment and dosing options so that patients can choose which best fits their lifestyle helps with this," Lees said.
Mirapexin prolonged-release has been proven to be an effective treatment in the control of motor symptoms at all stages of PD 2-4. Mirapexin has also been shown to significantly reduce depressive symptoms associated with PD 5-7.